PepBank has 10 Pancragen studies with results. 8 of them gave Pancragen, with 35 results, grouped by what the studies measured. In each group, results from studies in people come first. Data as of 2026-10-30.
Searches 35 results and 12 papers. Newer studies from Europe PMC
Identifiers, parent molecule, targets and development stage, from curated data.
Pancragen is a synthetic 4-residue peptide in the Khavinson bioregulator family. Its sequence is Lys-Glu-Asp-Trp with a C-terminal amide. Chemical identity does not establish a clinical benefit or a safe human dose.
No molecular target is recorded for this peptide.
Residues, differences from the parent, calculated properties and 3D structure. Source values and calculated values are shown separately.
4 amino acids · 1 modification
@pepdb/chem 0.2.0 · EMBOSS pKa set · ExPASy residue masses
pI 6.46 · Net charge at pH 7.4: −0.06
Point or use arrow keys
Henderson-Hasselbalch, EMBOSS pKa set, C-amide. Calculated, not measured.
| pH | Net charge |
|---|---|
| 0 | 2.00 |
| 1 | 2.00 |
| 2 | 1.98 |
| 3 | 1.81 |
| 4 | 1.00 |
| 5 | 0.19 |
| 6 | 0.02 |
| 7 | −0.02 |
| 8 | −0.20 |
| 9 | −0.73 |
| 10 | −1.10 |
| 11 | −1.61 |
| 12 | −1.94 |
| 13 | −1.99 |
| 14 | −2.00 |
4 residues. Each residue counts in one class; F and W count as aromatic.
No 3D structure
No experimental structure (PDB) and no UniProt entry for an AlphaFold model are listed for this peptide. Synthetic peptides often have neither. The sequence view above is the reference.
Draws the structure in your browser with RDKit (about 2.3 MB, loaded once).
SMILES fromPubChem CID 68451868(opens in a new tab)
C1=CC=C2C(=C1)C(=CN2)C[C@@H](C(=O)N)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)NPeople first in each area, then animals, then lab cells. Counts are exact and come from studies that gave the peptide.
PepBank reads each paper before it shows the results. This search looks in Europe PMC for newer papers that PepBank has not read yet.
Counts are exact and come from studies that gave the peptide.
Studies by year
10 of 12 studies have results (83%), published 2007 to 2015. Top row: every study. Bottom row: studies with results about Pancragen (KEDW), by class. The rows use different scales.
Studies12 in all, 2006 to 2015
Studies with results10 in all, 2007 to 2015
Retracted studies are left out. A study with results in two classes counts in both.
AI wrote and checked these results. AI can make mistakes, so check important results against the source.
Registered trials that test the peptide, with phase, status and dates. A dot marks trials with posted results.
0 trials match. Highest phase first. Data from ClinicalTrials.gov.
No trial matches these filters.
Studies on this peptide. Some have results. The others have none yet.
12 studies match. Retracted studies are left out.
Showing 10 of 12 studiesquery qry_784bafabed090b443ef68237
10 studies
Not a test of Pancragen (KEDW) alone · 2013
Fedoreyeva et al. 2013Biochemistry. Biokhimiiacited by 8
PMID 23581987DOI 10.1134/s0006297913020053PUB-23581987
In vitro (cells) · 2013
VKh et al. 2013Bulletin of experimental biology and medicinecited by 7
PMID 23486591DOI 10.1007/s10517-013-1987-6PUB-23486591
In vitro (cells) · 2012
VKh et al. 2012Bulletin of experimental biology and medicinecited by 6
PMID 22808515DOI 10.1007/s10517-012-1664-1PUB-22808515
Non-randomized trial · 2011
Korkushko et al. 2011Bulletin of experimental biology and medicinecited by 4
PMID 22448364DOI 10.1007/s10517-011-1354-4PUB-22448364
Animal study (in vivo) · rat · 2007
VKh et al. 2007Bulletin of experimental biology and medicinecited by 3
PMID 18642713DOI 10.1007/s10517-007-0377-3PUB-18642713
In vitro (cells) · 2012
VKh et al. 2012Advances in gerontology = Uspekhi gerontologiicited by 2
PMID 23734516DOI 10.1134/s2079057013030053PUB-23734516
Not a test of Pancragen (KEDW) alone · 2014
Tarnovskaya et al. 2014Bulletin of experimental biology and medicinecited by 1
PMID 24770759DOI 10.1007/s10517-014-2426-zPUB-24770759
Animal study (in vivo) · rhesus monkey · 2014
Goncharova et al. 2014Advances in gerontology = Uspekhi gerontologii
PMID 25946840PUB-25946840
Animal study (in vivo) · macaca mulatta · 2015
Goncharova et al. 2015Advances in gerontology = Uspekhi gerontologiin = 9
PMID 28509500PUB-28509500
Non-randomized trial · 2013
Korkushko et al. 2013Advances in gerontology = Uspekhi gerontologiin = 12
PMID 28976155PUB-28976155
These studies name Pancragen (KEDW) but give no result for it (for example, the results concern another peptide in the study).
Indexing hint: Animal study · 2010
VKh et al. 2010Bulletin of experimental biology and medicinecited by 4
PMID 21246099DOI 10.1007/s10517-010-0944-xPUB-21246099
Indexing hint: Animal study · 2006
Zakutskiĭ et al. 2006Advances in gerontology = Uspekhi gerontologii
PMID 17152728PUB-17152728
Page 1 of 1
Korkushko OV · Advances in gerontology = Uspekhi gerontologii · 2013
Non-randomized trial · 2 results
Korkushko OV · Bulletin of experimental biology and medicine · 2011
Non-randomized trial · 4 results
Goncharova ND · Advances in gerontology = Uspekhi gerontologii · 2015
Animal study (in vivo) · macaca mulatta · 5 results
Khavinson VKh · Bulletin of experimental biology and medicine · 2007
Animal study (in vivo) · rat · 3 results
Goncharova ND · Advances in gerontology = Uspekhi gerontologii · 2014
Animal study (in vivo) · rhesus monkey · 4 results
Khavinson VKh · Bulletin of experimental biology and medicine · 2013
In vitro (cells) · 7 results
Khavinson VKh · Bulletin of experimental biology and medicine · 2012
In vitro (cells) · 6 results
Khavinson VKh · Advances in gerontology = Uspekhi gerontologii · 2012
In vitro (cells) · 8 results
Fedoreyeva LI · Biochemistry. Biokhimiia · 2013
Not a test of Pancragen (KEDW) alone · 32 results
Tarnovskaya SI · Bulletin of experimental biology and medicine · 2014
Not a test of Pancragen (KEDW) alone · 3 results
Approval and sport status, and the safety outcomes reported in study results. Laws and labels change, so check the regulator for the current status.
| Jurisdiction | Body | Status | As of | Source |
|---|---|---|---|---|
| US | FDA | The cited Drugs@FDA search returned HTTP 404 and no matches for Pancragen, Pankragen and Lys-Glu-Asp-Trp. This name search does not establish all approval or compounding status. | 21 Oct 2026 | api.fda.gov (opens in a new tab) |
| EU | EMA | The cited EMA central medicine data contained no Pancragen, Pankragen or Lys-Glu-Asp-Trp match. This check does not cover EU national authorisations. | 21 Oct 2026 | ema.europa.eu (opens in a new tab) |
| Sport | WADA | Status unknown The peptide is not named in the 2026 list. | 2026 List | wada-ama.org (opens in a new tab) |
| Russia | Note | Human medicine registration was not established. The Russian medicine register was accessible, but a complete name and formulation search remains unresolved. | 21 Oct 2026 | grls.rosminzdrav.ru (opens in a new tab) |
Reported effects from study results.
No safety results from studies in people
The doses that these studies used. They are not recommendations.
500 mkg 2 times a day (morning and evening)Human
0,05 mg/animal per dayAnimal
50 μg/animal per dayAnimal
PepBank is a research reference. Talk to a doctor before you use any peptide.
Data version, change history and code for this peptide.
curl -s https://Evidence summary for Pancragen (KEDW): counts by class, key results with sources, notices, data version.
In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Top outcomes
The 3 outcome groups with the most study results, by evidence class.
Data version 308560. Bar length is the number of results, not the size of an effect.
Evidence matrix
Study results by outcome and evidence class. Arrows show how the measured outcome moved, not whether the change is good.
| Outcome group | Human | Animal | Lab | Computer model | Total |
|---|---|---|---|---|---|
| Glycemic controlMetabolic and weight | Human: 5 results from 2 studies: 5 decrease. Strongest design: Non-randomized trial | Animal: 10 results from 3 studies: 2 increase, 2 decrease, 6 not reported. Strongest design: Animal study (in vivo) | No results | No results | 15 |
| Cardiometabolic risk factorsCardiovascular | Human: 1 result from 1 study: 1 not reported. Strongest design: Non-randomized trial | No results | No results | No results | 1 |
| Receptor activity and mechanismEndocrine and hormones | No results | Animal: 2 results from 1 study: 1 no significant change, 1 not reported. Strongest design: Animal study (in vivo) | Lab: 17 results from 3 studies: 16 increase, 1 decrease. Strongest design: In vitro (cells) | No results | 19 |
3 outcome groups shown of 3 · 35 study results
Data version 308560. Shade grows with the number of results. Every cell shows the exact count.